Qiagen NVXTER:QIA +0.74%71 Net Margin % is 13.82% as of Mar. 2026, which is 8% below its 10-year median of 15.03. GuruFocus rates XTER:QIA with a GF Score™ of 71/100 and a GF Value™ of €45.90 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Qiagen NV ranks better than 91.13% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Qiagen NV's Net Income for the
three
months ended in Mar. 2026 was €59 Mil. Qiagen NV's Revenue for the
three
months ended in Mar. 2026 was €426 Mil. Therefore, Qiagen NV's net margin for the quarter that ended in Mar. 2026 was 13.82%.
The historical rank and industry rank for Qiagen NV's Net Margin % or its related term are showing as below:
XTER:QIA'
s Net Margin % Range Over the Past 10 Years
Min: -2.72 Med: 15.03 Max: 22.77
Current: 19.16
XTER:QIA's Net Margin % is ranked better than 91.13% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.43
vs XTER:QIA: 19.16
Qiagen NV (XTER:QIA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Qiagen NV Net Margin % Related Terms
Qiagen NV Net Margin % Historical Data
* Premium members only.
The historical data trend for Qiagen NV's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:QIA vs TWST, CRL, BLLN: Net Margin % Comparison
For the Diagnostics & Research subindustry, Qiagen NV's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qiagen NV Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Net Margin % distribution charts can be found below:
* The bar in red indicates where Qiagen NV's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qiagen NV (XTER:QIA) has a Net Margin % of 13.82% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Qiagen NV and its competitors. This is near median its historical median of 15.03. According to the industry distribution chart, Qiagen NV ranks #18 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 8.9%.
Is Qiagen NV's Net Margin % too high?
Qiagen NV's current Net Margin % of 13.82% is near median its 10-year median of 15.03. Based on the distribution chart, Qiagen NV ranks #18 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Qiagen NV has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Net Margin % compare to TWST and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Qiagen NV ranks #18 out of 203 companies for Net Margin %. This places Qiagen NV in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Qiagen NV and its competitors. Qiagen NV's current Net Margin % is 13.82%, which is near median its own 10-year median of 15.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.90, compared to a current price of €34.57 — trading 24.7% below its estimated fair value. The current Net Margin % is 13.82%, which is near median its 10-year median of 15.03. Qiagen NV's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current Net Margin % is 13.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qiagen NV (XTER:QIA) Overvalued in 2026?
Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued.
The current stock price of €34.57 is trading 24.7% below its estimated GF Value™ of €45.90.
GuruFocus considers Qiagen NV to be Modestly Undervalued.
Key valuation signals for XTER:QIA:
Net Margin %: 13.82% (near median its 10-year median of 15.03)
GF Value™: €45.90 vs. price of €34.57 (24.7% below fair value)
No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
71GF Score
Get the complete analysis for XTER:QIA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:QIA has been successfully added to your 
